Amgen announced positive topline Subcutaneous TEPEZZA Phase 3 results, delivered through an on-body injector, in adults with moderate-to-severe active Thyroid Eye Disease. In its official release, the company said the study met its primary and key secondary endpoints, with a 77% proptosis response rate during the 24-week placebo-controlled period and a mean proptosis reduction of 3.17 mm. Amgen also said the subcutaneous version provides comparable efficacy to intravenous TEPEZZA.

What the Phase 3 results showed

The topline results are important because TED treatment has so far been strongly associated with intravenous administration. Amgen’s press release states that the subcutaneous TEPEZZA OBI study met the primary endpoint and showed clinically meaningful reduction in proptosis, which is one of the most visible and burdensome symptoms of the disease.

The company also described the efficacy as “IV-level,” indicating that the new delivery format is intended to preserve the therapeutic value of the original formulation while reducing the burden of infusion-based treatment. 

Amgen further said the overall safety results were generally consistent with the known safety profile of IV TEPEZZA. Mild-to-moderate injection site reactions were reported in some patients, but the company said these did not lead to treatment interruption or discontinuation. 

Why this could matter clinically

The biggest practical value of the result is convenience. A subcutaneous on-body injector is less invasive and potentially easier to deliver than recurring IV infusions, especially for patients who face logistical, time or access barriers. Biopharma Dive reported that the result could help Amgen defend and extend TEPEZZA’s position in TED by offering an under-the-skin option that remains comparable to the infused version in efficacy and safety. 

That matters because TED is not only a cosmetic issue. Amgen’s release describes it as a serious, progressive and potentially vision-threatening autoimmune disease that can cause eye bulging, double vision, pain, redness and swelling. In that context, a more accessible delivery option could change treatment experience for many patients even if the drug itself is not new. 

Also Read: AI Mental Health Ecosystem: How Technology Is Becoming a Lifeline in 2025

The result is promising, but still a topline announcement

One important caution is that these are topline Phase 3 results from the company, not yet a final regulatory outcome. The findings are clearly encouraging, but the next milestones will include detailed data presentation, regulatory review, and how physicians assess the real-world practicality of the on-body injector format.

That is not a weakness in the result, just a normal part of the clinical-development process. This is an inference based on the status of the company’s announcement and the usual regulatory pathway. 

A useful shift in treatment design

This development shows that innovation is not only about discovering entirely new medicines. Sometimes real progress comes from changing how an effective therapy is delivered. That can mean less discomfort, less disruption and wider practical access, which may matter enormously to people living with chronic or highly visible disease. This is an inference, but it follows from the contrast between IV administration and the new subcutaneous format. 

Better care should become easier to reach

Medical progress matters most when it reduces suffering in ways people can actually use. In a broader ethical sense, that aligns with the teaching that human effort should be directed toward relief, compassion and practical welfare. A treatment that becomes less burdensome while preserving effectiveness is a meaningful example of science serving people more directly. 

Call to Action

The next things to watch are regulatory submission, full data release, and whether clinicians view subcutaneous TEPEZZA as a genuine practice-changing option rather than only a convenience upgrade. Those steps will determine how quickly this promising result turns into real patient access. 

FAQs: Subcutaneous TEPEZZA Phase 3 Results

1. What did Amgen announce?

Amgen announced positive topline Phase 3 results for subcutaneous TEPEZZA in adults with moderate-to-severe active Thyroid Eye Disease. 

2. What was the key efficacy result?

The company reported a 77% proptosis response rate and a mean proptosis reduction of 3.17 mm at week 24. 

3. Is the new version subcutaneous?

Yes. It was administered via a subcutaneous on-body injector. 

4. How did Amgen compare it with IV TEPEZZA?

Amgen said it provides comparable efficacy to IV TEPEZZA. 

5. What about safety?

Amgen said the safety results were generally consistent with IV TEPEZZA, with mild-to-moderate injection site reactions in some patients. 

6. Does this mean the new version is already approved?

Not yet. These are topline Phase 3 results, so regulatory steps still remain.